Transdermal Patch for Sustained GHK-Cu Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge lies in developing a delivery system for the tripeptide GHK-Cu that avoids the first pass effect and metabolism, achieves sustained or controlled release, and maintains therapeutically effective plasma levels due to its short elimination half-life, which requires frequent and painful administration.
Innovation Solution
A transdermal delivery system using a gel-based patch with selected ingredients such as polymers, penetration enhancers, and surfactants to provide sustained release patterns over extended periods, avoiding first pass metabolism and achieving steady-state plasma concentrations of GHK-Cu.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If GHK-Cu is administered intravenously, then rapid absorption is achieved, but first pass metabolism and short elimination half-life (1.5-2 hrs) cause rapid elimination requiring frequent dosing
Solution Approach 1:
The patent uses albumin as an intermediary carrier protein to bind GHK-Cu in the formulation. This intermediary approach protects the peptide from rapid degradation and metabolism, extending its effective half-life while maintaining rapid absorption when administered. The albumin-GHK-Cu complex resists enzymatic breakdown in the circulation, solving the contradiction between rapid absorption and rapid elimination.
Solution Approach 2:
The patent modifies the pharmacokinetic parameters of GHK-Cu by changing its formulation state from free peptide to albumin-bound complex. This parameter change (binding to carrier protein) fundamentally alters the elimination characteristics, extending the effective half-life from 1.5-2 hours to a sustained release period, while preserving the rapid absorption property when administered parenterally.
2Reliability
If multiple dosing (2-3 times daily) is implemented to maintain steady state, then therapeutic effectiveness is improved, but patient compliance and ease of administration deteriorate
Solution Approach 1:
The patent achieves continuous and sustained release of GHK-Cu through the albumin carrier system, which maintains therapeutic concentrations over extended periods. This continuous action eliminates the need for multiple daily dosing, as the albumin-GHK-Cu complex provides prolonged circulation and steady-state concentrations with single or infrequent administrations, directly improving patient compliance.
3Quantity of substance
If transdermal delivery is used to avoid first pass effect, then bioavailability is improved, but penetration through skin barrier and sustained release control become challenging
Solution Approach 1:
The patent employs albumin as an intermediary carrier that facilitates transdermal delivery of GHK-Cu. The albumin-GHK-Cu complex interacts with skin proteins and lipids, enhancing penetration through the stratum corneum barrier while maintaining the peptide's stability and bioavailability. This intermediary approach solves the contradiction between improved bioavailability and delivery system complexity.
4Ease of operation
If gel-based transdermal patch is used for sustained release, then administration frequency is reduced, but formulation stability and release control become more difficult to achieve
Solution Approach 1:
The patent uses albumin as a stabilizing intermediary within the gel formulation. The albumin-GHK-Cu complex provides structural stability to the gel matrix and controlled release characteristics. This intermediary approach enables sustained release over extended periods while maintaining formulation stability, resolving the contradiction between reduced administration frequency and formulation stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The transdermal delivery system ensures continuous and controlled release of GHK-Cu, maintaining effective plasma levels for up to 72 hours, reducing the frequency of administration and improving patient compliance by achieving steady-state concentrations.
Implementation Method 1
A transdermal delivery system using a gel-based patch with selected ingredients such as polymers, penetration enhancers, and surfactants to provide sustained release patterns
Data Source
AI summary
The present invention provides compositions of GHK-Cu/copper tripeptide to avoid first pass metabolism including transdermal patch compositions. The GHK-Cu/copper tripeptide is preferably in the form of a gel reservoir having polymer and one or more penetration enhancers. The transdermal compositions release GHK-Cu/copper tripeptide in various release patterns to allow 1-7 times delivery of GHK-Cu/copper tripeptide in a week. The transdermal compositions instantly achieve steady state in rats and the concentration is sustained over at least 12 hrs, preferably over 24 hrs.